Bio-Rad Laboratories, Inc. (BIO) CFO Christine A. Tsingos Sells 4,980 Shares of Stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) CFO Christine A. Tsingos sold 4,980 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $249.40, for a total transaction of $1,242,012.00. Following the completion of the sale, the chief financial officer now directly owns 7,283 shares of the company’s stock, valued at $1,816,380.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Bio-Rad Laboratories, Inc. (NYSE:BIO) traded up $2.22 during mid-day trading on Friday, reaching $251.94. 338,400 shares of the company were exchanged, compared to its average volume of 179,899. The firm has a market cap of $7,491.65, a PE ratio of 79.91, a PEG ratio of 3.76 and a beta of 0.97. The company has a quick ratio of 2.77, a current ratio of 4.06 and a debt-to-equity ratio of 0.15. Bio-Rad Laboratories, Inc. has a one year low of $177.68 and a one year high of $273.87.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.54 by $0.37. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. The business had revenue of $535.00 million during the quarter, compared to analysts’ expectations of $507.99 million. During the same period in the previous year, the business posted $0.62 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 2.68 earnings per share for the current year.

Bio-Rad Laboratories declared that its board has initiated a stock repurchase plan on Tuesday, November 28th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

BIO has been the subject of several research analyst reports. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. TheStreet upgraded shares of Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a report on Monday, November 13th. Deutsche Bank restated a “buy” rating and issued a $255.00 target price on shares of Bio-Rad Laboratories in a report on Monday, September 18th. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $290.00 target price (up previously from $250.00) on shares of Bio-Rad Laboratories in a report on Wednesday, November 29th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $277.75.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Investment Management Company LLC increased its holdings in Bio-Rad Laboratories by 0.4% in the 2nd quarter. Northwestern Mutual Investment Management Company LLC now owns 3,596 shares of the medical research company’s stock worth $514,000 after acquiring an additional 13 shares in the last quarter. World Asset Management Inc grew its holdings in shares of Bio-Rad Laboratories by 1.4% during the second quarter. World Asset Management Inc now owns 1,025 shares of the medical research company’s stock worth $232,000 after buying an additional 14 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Bio-Rad Laboratories by 1.8% during the second quarter. Teacher Retirement System of Texas now owns 1,666 shares of the medical research company’s stock worth $377,000 after buying an additional 29 shares in the last quarter. Martin & Co. Inc. TN grew its holdings in shares of Bio-Rad Laboratories by 0.6% during the second quarter. Martin & Co. Inc. TN now owns 6,825 shares of the medical research company’s stock worth $1,545,000 after buying an additional 40 shares in the last quarter. Finally, State of Wisconsin Investment Board grew its holdings in shares of Bio-Rad Laboratories by 1.0% during the second quarter. State of Wisconsin Investment Board now owns 4,187 shares of the medical research company’s stock worth $948,000 after buying an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 63.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://stocknewstimes.com/2017/12/15/bio-rad-laboratories-inc-bio-cfo-christine-a-tsingos-sells-4980-shares-of-stock.html.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply